Mylan Launches First Generic Maxalt MLT® Tablets

               Mylan Launches First Generic Maxalt MLT® Tablets

- Company also launching immediate-release version Maxalt® Tablets -

PR Newswire

PITTSBURGH, Jan. 2, 2013

PITTSBURGH, Jan. 2, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
announced that its subsidiary Mylan Pharmaceuticals has received final
approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated
New Drug Applications (ANDA) for Rizatriptan Benzoate Orally Disintegrating
Tablets, 5 mg (base) and 10 mg (base), and Rizatriptan Benzoate Tablets, 5 mg
(base) and 10 mg (base). These products are the generic versions of Merck's
Maxalt MLT® Tablets and Maxalt® Tablets, respectively, and are indicated for
the acute treatment of migraine with or without aura in adults.

Mylan was the first company to have filed a substantially complete ANDA
containing a Paragraph IV certification for Rizatriptan Benzoate Orally
Disintegrating Tablets, 5 mg (base) and 10 mg (base), and was awarded 180 days
of marketing exclusivity.

Mylan CEO Heather Bresch commented: "Mylan's immediate launch of the first
generic Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg (base) and 10
mg (base), and the company's simultaneous launch of Rizatriptan Benzoate
Tablets, 5 mg (base) and 10 mg (base), further demonstrates our commitment to
continue expanding access to high quality medicines for patients who need them
in the U.S. and around the world. We look forward to continue growing our
portfolio of more than 1,100 generic pharmaceutical products to further
support this cause."

Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg (base) and 10 mg
(base), had U.S. sales of approximately $262.5 million for the 12 months
ending Sept. 30, 2012, according to IMS Health, and Rizatriptan Benzoate
Tablets, 5 mg (base) and 10 mg (base), had U.S. sales of approximately $344.7
million for the same period. Mylan is shipping the orally disintegrating and
immediate-release versions of this product immediately.

Currently, Mylan has 183 ANDAs pending FDA approval representing $79.9 billion
in annual sales, according to IMS Health. Thirty-four of these pending ANDAs
are potential first-to-file opportunities, representing $20.8 billion in
annual brand sales, for the 12 months ending June 30, 2012, according to IMS
Health.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service a habit, do what's right, not what's easy and impact
the future through passionate global leadership. We offer a growing portfolio
of more than 1,100 generic pharmaceuticals and several brand medications. In
addition, we offer a wide range of antiretroviral therapies, upon which
approximately one-third of HIV/AIDS patients in developing countries depend.
We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 150 countries and
territories. Our workforce of more than 18,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com

SOURCE Mylan Inc.

Website: http://www.mylan.com
Contact: Nina Devlin (Media), +1-724.514.1968; Kris King (Investors),
+1-724.514.1813
 
Press spacebar to pause and continue. Press esc to stop.